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Here, the influence of β3-adrenoceptors on catecholamine release in normotensive and
spontaneously hypertensive rats was analyzed. Blood pressure was recorded through
a femoral artery catheter, and cardiac output by ascending aorta flow. Time from
onset of flow to maximum rise in flow indicated inotropy. Total peripheral vascular
resistance (TPR) was calculated. Norepinephrine release was stimulated with tyramine,
which allowed presynaptic release-control to be reflected as changes in the plasma
norepinephrine concentration. β3-adrenoceptor agonist (BRL37344) reduced baseline
vascular resistance, the tyramine-stimulated norepinephrine overflow and the positive
inotropic response to tyramine in hypertensive but not normotensive rats. β3-adrenoceptor
antagonist (SR59230A) reduced tyramine-stimulated norepinephrine release in both
strains and the secretion of epinephrine in hypertensive rats. SR59230A reduced
tyramine-induced tachycardia in normotensive rats, and prevented down-regulation of
the tyramine-induced rise in resistance in hypertensive rats. It was concluded that the
contradicting results obtained by agonist vs. antagonist, could be explained by their
interaction with two different β-adrenoceptors: The BRL37344-dependent inhibition of
stimulated norepinephrine release and positive inotropic response to tyramine was
compatible with stimulation of β3-adrenoceptor coupling to inhibitory G-protein. This
was observed only in hypertensive rats during stimulated, high levels of circulating
catecholamines. The effect of BRL37344 on baseline vascular resistance was compatible
with activation of β3-adrenoceptor coupling to endothelial nitric oxide synthase. The
inhibitory effect of SR59230A on tyramine-stimulated norepinephrine release in both
strains, the increased TPR-response to tyramine in hypertensive rats and tachycardia in
normotensive rats may result from inhibition of the low-affinity-state β1-adrenoceptor, also
known as the putative β4-adrenoceptor.
Keywords: β3-adrenoceptors, putative β4-adrenoceptors, norepinephrine release, epinephrine secretion,
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INTRODUCTION
The release of norepinephrine from vesicles in peripheral sym-
pathetic nerve terminals is modulated by presynaptic recep-
tors, which either inhibit or stimulate release (Westfall, 1977;
Starke et al., 1989). Of the three β-adrenoceptor (AR) sub-
types, i.e., β1-, β2- and β3AR, the β2-subtype has been recog-
nized as the main βAR which stimulates norepinephrine release
(Stjarne and Brundin, 1976; Westfall et al., 1979; Nedergaard
and Abrahamsen, 1990). However, during tyramine-induced
norepinephrine release, presynaptic β1AR was recently found to
be equally efficient as the β2AR in stimulating the release of
norepinephrine (Berg, 2014). However, their effect was not addi-
tive, since blocking both was not more efficient than blocking
one or the other. Little is known about the role of the β3AR
in modulating norepinephrine release, although an increase in
norepinephrine transmission, probably in the locus coeruleus,
has been observed after central stimulation with the β3AR ago-
nist SR58611A (Claustre et al., 2008). However, unlike β1- and
β2AR, the β3AR may couple not only to stimulatory G-protein
(Gs) but also to inhibitory G-protein (Gi) (Gauthier et al., 1996).
Through this, the β3AR may activate nitric oxide (NO) synthase
(NOS), most likely endothelial NOS (eNOS), and produce a neg-
ative inotropic effect in cardiomyocytes (Gauthier et al., 1998).
In the vasculature, β3AR, through coupling to Gs, may induce
vascular smooth muscle cell (VSMC) relaxation directly, or indi-
rectly through endothelial eNOS activation (for review, see Rozec
and Gauthier, 2006). If the β3AR will inhibit or facilitate nore-
pinephrine release from peripheral sympathetic nerve terminals
is not known. In cultured human adrenal chromaffin cells, β2AR
and β3AR, but not β1AR, were found to stimulate release of both
norepinephrine and epinephrine (Cortez et al., 2012). Similar
studies have not been done on the rat adrenal gland or in vivo.
Little is known about the role of the β3AR in hypertension. A
missense mutation in the β3AR gene was associated with hyper-
tension (Tonolo et al., 1999; Ringel et al., 2000; Hao et al., 2004)
and other features of the metabolic syndrome such as insulin
resistance and in some populations, overweight/obesity and dys-
lipidemia (Widen et al., 1995; Arner and Hoffstedt, 1999; Thomas
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et al., 2000). This mutation was also associated with an increased
sensitivity to the pressor effect of exogenous norepinephrine
(Melis et al., 2002), similar to the augmented rise in total periph-
eral vascular resistance (TPR) during stimulated norepinephrine
release in the presence of β3AR antagonist (Berg et al., 2010). The
β3AR is more resistant to catecholamine-induced desensitization
than β1/2AR, and is preserved and present in a higher density
compared to the β1AR in SHR (Mallem et al., 2004; Rouget et al.,
2004). This difference may contribute to the altered presynaptic
control of catecholamine release known to be present in spon-
taneously hypertensive rats (SHR) (Berg, 2013; Berg and Jensen,
2013).
It was therefore hypothesized that β3AR are located presy-
naptically on peripheral sympathetic nerve endings and adrenal
chromaffin cells, where they may either lower or facilitate release,
and that their function may be more prominent in hyperten-
sion. The aim of the present study was therefore to decipher the
role of β3AR in the control of catecholamine release in SHR and
their normotensive controls (WKY). Presynaptic control of nore-
pinephrine release was studied by the use of tyramine, which
selectively activates the release of norepinephrine from periph-
eral sympathetic nerve terminals by stimulating reverse transport
through the norepinephrine re-uptake transporter (NET). When
NET is blocked (Berg et al., 2012), or engaged in release in the
presence of tyramine (Berg and Jensen, 2013), re-uptake is pre-
vented, and the impact of presynaptic control of vesicular release
is reflected as differences in overflow to plasma (Berg, 2013, 2014)
(Figure 1). The presynaptic receptors are activated by the released
norepinephrine and other agonists present in their vicinity. The
release of norepinephrine is therefore not directly dependant on
the sympathetic tone, which will be influenced by factors such
anesthesia, ventilation and rat strain, but activated pharmacolog-
ically in the nerve terminal. The surgical trauma was responsible
for some secretion of epinephrine, also subjected to presynaptic
control (Berg et al., 2012). The present study is the first to anal-
yse in vivo the role of β3AR in catecholamine release in WKY and
SHR, and, in the same animal, their impact on inotropy, heart
rate (HR) and TPR.
MATERIALS AND METHODS
EXPERIMENTAL PROCEDURE
All experiments were approved by The Norwegian Animal
Research Authority (NARA) (approval number 10.2914), and
conducted in accordance with the Directive 2010/63/EU of the
European Parliament. Fifty-eight male, 12–14 weeks old SHR
(Okamoto, SHR/NHsd strain, 281 ± 3 g body weight) and 55
age-matchedWKY (Wistar Kyoto, 282± 3 g body weight) on con-
ventional rat chow diet (0.7% NaCl) were included in the study.
As previously described (Berg et al., 2010), the rats were anes-
thetized with sodium pentobarbital (65–75mg/kg, IP). The level
of surgical anesthesia was tested by non-responsiveness to pinch-
ing between the toes. When satisfactory anesthesia was estab-
lished, it remained throughout the experiment without further
supply. The rats were instrumented with a heparinized catheter in
the femoral artery to record systolic (SBP) and diastolic (DBP)
blood pressure (BP), and a flow probe on the ascending aorta
to measure cardiac output (CO) and HR. Mean arterial BP
FIGURE 1 | An overview of the experimental design to test the role of
β3AR in catecholamine release. The presynaptic βARwill be activated by the
released norepinephrine or by circulating epinephrine from the adrenals.
Dotted arrows; tested, but not verified hypothesis. ∗; effect observed in SHR
only in response to β3AR antagonist (adrenal) and antagonist (neuronal). NE,
norepinephrine; E, epinephrine; NET, norepinephrine re-uptake transporter.
[MBP = (SBP–DBP)/3 + DBP] and TPR (MBP/CO) were calcu-
lated. TF (time from onset of ascending aorta flow to maximum
rise in flow, derived from high resolution aorta flow data, i.e.,
5000 points during a 2-s collection-period, stored when pressing
a specified key on the computer) was used to indicate changes in
inotropy (Berg et al., 2010). A negative change in TF indicated a
positive inotropic response, and vice versa. The rats were kept on
a positive-pressure respirator and ventilated with air throughout
the experiment. Body temperature was maintained by external
heating, guided by a thermo sensor inserted inguinally into the
abdominal cavity. Removal of the adrenal glands (AdrX) was done
through bilateral flank incisions at the start of the surgical proce-
dure, i.e., 30min before injecting the first drug. At completion of
the experiment, the animals were sacrificed by an IV injection of
about 35mg pentobarbital.
EXPERIMENTAL PROTOCOLS
All drugs were dissolved in phosphate-buffered saline (PBS;
0.01M Na-phosphate, pH 7.4, 0.14M NaCl) and administered
through a catheter in the femoral vein. After a control period of
about 10min, control rats were pre-treated with PBS (0.6ml/kg,
bolus injection), followed 10min later by a 15min infusion
with tyramine (1.26μmol/kg/min) to stimulate norepinephrine
release (Berg et al., 2010, 2012). In time control rats, tyramine
was replaced by an infusion with PBS. To test the influence of
β3AR on release control, the rats were pre-treated with the β3AR
agonist BRL37344 ((±)-(R∗, R∗)-[4-[2-[[2-(3-Chlorophenyl)-
2-hydroxyethyl]amino]propyl]phenoxy]-acetic acid sodium
hydrate) infused at a rate of 1 nmol/kg/min (Malinowska
and Schlicker, 1997) for 10min, and subsequently combined
with tyramine throughout the tyramine infusion-period.
Alternatively, rats were pre-treated with the β3AR antagonist
SR59230A (13.8μmol/kg, 0.6ml/kg, bolus injection) 5min
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before administration of tyramine, as previously described (Berg
et al., 2010). These experiments were run in not-AdrX and
AdrX rats to study the influence of circulating epinephrine on
β3AR activity, and if the effect of β3AR agonist and antagonist
influenced norepinephrine release indirectly by altering adrenal
epinephrine secretion. To study the effect of presynaptic β3AR on
norepinephrine release in the absence of β1+2AR stimulation of
release and without interference from the adrenals, AdrX WKY
and SHR were pre-treated with the β1AR antagonist CGP20712A
(11μmol/kg, 0.6ml/kg, bolus injection) followed 10 min later
by the β2AR antagonist ICI-118551 (1μmol/kg initial dose,
subsequently infused with 0.3μmol/kg/min for 10min), alone or
with SR59230A injected 5min into the infusion of ICI-118551
(Berg et al., 2010). Tyramine was subsequently infused combined
with ICI-118551. An overview of drug actions and hypotheses
tested are given in Figure 1. The rats in the antagonist and control
groups were in part the same as in a previous study (Berg et al.,
2010), where the plasma concentration of catecholamines were
not measured, except in the AdrX CGP20712A + ICI-118551 +
tyramine SHR group. Additional rats were included to overlap in
time with the BRL37344-groups, and to have sufficient numbers
of plasma when remaining plasma from old controls and the
CGP20712A + ICI-118551-treated AdrX SHR group was not
sufficient to repeat the measurement of catecholamines with our
present assay, which differed from that previously employed. The
cardiovascular response in these additional rats corresponded
to that observed before (Berg et al., 2010). Previously published
cardiovascular data will therefore be only shortly summarized,
to be included in the discussion of the interpretation of the
data, in light of the present new information, i.e., the plasma
catecholamine concentrations after β3AR agonist and antagonist,
as well as the cardiovascular response to agonist. The number
of rats included in each group (Table 1) was based on sample
power calculations using previous data from similar or related
experiments.
MEASUREMENT OF PLASMA CATECHOLAMINES
At the end of the tyramine infusion, without discontinu-
ing the infusion, 1.5ml blood was collected by free flow
from the femoral artery catheter, into tubes containing 40μl
0.2M glutathione, 0.2M ethylene glycol-bis(2-aminoethylether)-
N,N,N′,N′-tetraacetic acid (EGTA) (4◦C). Plasma was stored
at −80◦C until catecholamine concentrations were determined
using 400μl plasma and the 5000 Reagent kit for HPLC anal-
ysis of Catecholamines in plasma from Chromsystems GmbH,
Munich, Germany, as described by the manufacturer. The sam-
ples were run on a Shimadzu monoamines analyzer system, using
an isocratic flow rate of 0.8ml/min, and an electrochemical detec-
tor (Decade II) and a SenCell electrochemical flow cell (Antec
Leyden, Zoeterwoude, The Netherlands).
DRUGS
SR59230A was from Santa Cruz Biotechnology, Heidelberg,
Germany, and ICI-118551 from ICI-Pharma, Cheshire, UK.
BRL37344 and tyramine were from Sigma Chemical Co., St.
Louis, MO, USA.
STATISTICAL ANALYSES
The results are presented as mean values ± s.e.m. The plasma
catecholamine concentrations were evaluated by overall tests
(One-Way ANOVA). When the presence of significant group
differences was indicated, these were located by two-sample
Student’s t-tests for parametric data, and by Kruskal-Wallis tests
for non-parametric data. P ≤ 0.05 was considered significant.
The cardiovascular data were averaged every min. The car-
diovascular response to pre-treatment and baselines prior to
tyramine were evaluated by One-Way ANOVA, including all
groups within each strain.When the presence of group differences
was indicated, these were subsequently located by two-sample
Student’s t-tests and Kruskal-Wallis tests for parametric and non-
parametric results, respectively. The tyramine response-curves
Table 1 | The plasma concentration of norepinephrine and epinephrine.
WKY SHR
N Norepinephrine Epinephrine N Norepinephrine Epinephrine
(nM) (nM) (nM) (nM)
PBS + PBS (not-AdrX | time control) 6 0.7±0.2 6.9±1.2 6 1.3±0.2 10.9± 1.9
PBS + tyramine (not-AdrX control) 9 21.5±1.2* 3.9±1.2 9 27.2±1.3*† 5.8± 0.9
BRL37344 + tyramine (not-AdrX) 7 26.1±3.5 4.9±2.3 6 21.8±1.2‡ 5.4± 1.1
SR59230A + tyramine (not-AdrX) 10 14.9±2.1‡ 1.8±0.6 9 21.2±1.6‡ 2.7± 1.0‡
AdrX + PBS + PBS (AdrX time control) 6 0.2±0.1 0.0±0.0 8 3.7±1.3 0.3± 0.2
AdrX + PBS + tyramine (AdrX control) 6 21.7±2.4* 0.7±0.7−| 6 33.2±4.0*† 0.1± 0.1−|
AdrX + BRL37344 + tyramine 8 17.3±1.9−| 0.0±0.0−| 6 34.6±5.7−| 0.0± 0.0−|
AdrX + SR59230A + tyramine 8 22.6±2.9−| 0.4±0.4−| 7 33.2±5.1−| 0.4± 0.3−|
AdrX + CGP20712A + ICI-11855 + tyramine 7 16.7±2.4 0.6±0.4 7 37.7±5.3 0.2± 0.2
AdrX + CGP20712A + ICI-11855 + SR59230A + tyramine 6 12.8±1.3‡ 0.9±0.9 6 25.6±6.5 0.5± 0.5
Significant differences between the time controls and corresponding tyramine control groups (*), between the SHR and WKY PBS + tyramine groups in not-AdrX
and AdrX rats († after SHR values), between corresponding PBS + tyramine and agonist/antagonist + tyramine groups (‡), and between corresponding not-AdrX and
AdrX groups (−|), were detected as indicated. Significant differences between the AdrX + CGP20712A + ICI-11855 + tyramine and AdrX + CGP20712A + ICI-11855
+ SR59230A + tyramine groups were not detected. N, number of rats per group. *, †, ‡, −| — P ≤ 0.05.
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were analyzed using Repeated Measures Analyses of Variance and
Covariance, first as over-all tests including all groups within each
strain, and subsequently between groups and for each group sep-
arately. Significant responses (one-sample Student’s t-tests) and
groups differences (two-sample Student’s t- or Kruskall-Wallis
tests) were subsequently located at specific times, i.e., at the initial
peak-pressure response (about 3min) and/or after 15min. For
each step, testing proceeded only when the presence of signifi-
cant responses, differences and/or interactions was indicated, and
the P-value was for all tests and each step adjusted according to
Bonferroni.
RESULTS
EFFECT OF β3AR-AGONIST AND -ANTAGONIST ON THE PLASMA
CATECHOLAMINE CONCENTRATIONS (TABLE 1)
Tyramine clearly increased the plasma concentration of
norepinephrine in both not-AdrX and AdrX rats of both strains
(P < 0.001 compared to the time controls infused with PBS
instead of tyramine), but did not significantly influence the
epinephrine concentration. At the end of the tyramine-infusion
period, the plasma concentration of norepinephrine was higher
in SHR than inWKY in not-AdrX as well as AdrX rats (P = 0.005
and 0.037, respectively). The concentration of norepinephrine in
AdrX rats was not different from that in the not-AdrX controls
(P = NS), showing that the tyramine-stimulated overflow of
norepinephrine involved sympathetic nerves rather than the
adrenals. The plasma concentration of epinephrine was almost
totally eliminated in AdrX rats (P = 0.029 and 0.001 compared
to not-AdrX WKY and SHR, respectively).
The β3AR-agonist BRL37344 did not alter the tyramine-
induced norepinephrine overflow to plasma in WKY (P = NS)
but reduced overflow in SHR (P = 0.011), suggesting β3AR to
have a negative influence on release in this strain. In contrast
to this result, the β3AR-antagonist SR59230A was observed to
lower norepinephrine overflow, and did so in both strains (P =
0.006 and 0.032 in WKY and SHR, respectively). SR59230A and
BRL37344 had no significant effect on norepinephrine overflow
in AdrX WKY and SHR.
In AdrX rats, pre-treatment with β1- and β2AR antagonist, i.e.,
CGP20712A + ICI-118551, followed by SR59230A reduced the
tyramine-stimulated norepinephrine overflow (P = 0.018 com-
pared to the AdrX WKY controls), whereas the almost same
reduction following CGP20712A + ICI-118551 alone was not
statistically significant. The reduction seen in CGP20712A + ICI-
118551 + SR59230A-pre-treated AdrX SHR was not statistically
significant (P = NS compared to the AdrX SHR controls).
BRL37344 had no effect on the plasma epinephrine concentra-
tion in either strain (P = NS). However, SR59230A reduced the
plasma epinephrine concentration in both strains, although the
difference was statistically significant in SHR only (P = 0.034).
EFFECT OF β3AR-AGONIST AND -ANTAGONIST ON CARDIOVASCULAR
BASELINES
BRL37344 reduced MBP (−11 ± 2 compared to the −1 ± 2mm
Hg following the injection of PBS in the controls, P = 0.005)
in WKY, increased CO in both strains (9 ± 2 and 4 ±
1ml/min in WKY and SHR, respectively, compared to 3 ± 0 and
1 ± 1ml/min in the controls) and in AdrX WKY (7 ± 1 com-
pared to 3 ± 1ml/min in the controls) (P ≤ 0.006). The effect of
BRL37344 on TPR baseline was not significant in WKY or SHR
(P = NS). However, BRL37344 reduced baseline TPR in the AdrX
WKY (−0.9 ± 0.1mm Hg/ml/min compared to −0.4 ± 0.1mm
Hg/ml/min after PBS) and AdrX SHR (−1.2 ± 0.4 and −0.4 ±
0.4mm Hg/ml/min, respectively). The resulting TPR after pre-
treatment, i.e., prior to tyramine, was 2.4 ± 0.3 and 1.9 ± 0.1mm
Hg/ml/min after PBS and BRL37344, respectively in the WKY
controls, 2.1 ± 0.1 and 1.9 ± 0.2mm Hg/ml/min, respectively, in
AdrXWKY, and 5.0 ± 0.3, 4.8 ± 0.3, 6.6 ± 0.9 (P = NS compared
to the control group) and 3.6 ± 0.8 (P = 0.034) mm Hg/ml/min
in the corresponding SHR groups. BRL37344 reduced TF (i.e.,
increased inotropy) in SHR (TF = −6 ± 4 compared to 4± 3%
in the controls) and in AdrX SHR (TF = −7 ± 3 compared to
2± 5% in the controls) (P ≤ 0.01). As previously described (Berg
et al., 2010), the antagonist SR59230A increased baseline MBP
and reduced TF (i.e., indicating an increase in inotropy) in WKY
(P ≤ 0.004), and increasedMBP and CO and reduced TF in AdrX
WKY (P ≤ 0.018) (data not shown). A change in baseline TF was
not observed in AdrX WKY when SR59230A was given after β1-
and β2AR blockade with CGP20712A and ICI-118551 (−8 ± 2%
compared to 1 ± 2% in the control group, P = 0.041). SR59230A
had no effect on TPR baseline in not-AdrX or AdrX WKY or
any of the cardiovascular baselines in not-AdrX or AdrX SHR.
TPR after SR59230A was 3.3 ± 0.3 and 3.3 ± 0.4mm Hg/ml/min
in WKY and AdrX WKY, respectively, and 5.4 ± 0.4 and
7.3 ± 0.8mm Hg/ml/min in the corresponding SHR groups.
EFFECT OF β3AR-AGONIST AND -ANTAGONIST ON THE
CARDIOVASCULAR RESPONSE TO TYRAMINE
BRL37344 reduced the tyramine-induced fall in TF in not-AdrX
SHR (−23 ± 2 compared to −36 ± 2% in the controls, P =
0.018), demonstrating a counter-action of the positive inotropic
response to tyramine. BRL37344 had no effect on the tyramine-
induced, sustained tachycardia in none of the groups (data not
shown). The same pattern was seen regardless of expressing the
change in bpm or in percentage of HR baseline. As previously
described (Berg et al., 2010), SR59230A clearly reduced the tachy-
cardia in WKY and AdrXWKY but had no effect in SHR or AdrX
SHR. The rise in TPR in response to tyramine was augmented
by BRL37344 throughout the tyramine infusion-period in AdrX
SHR when expressed in percentage of baseline (Figure 2), but
not when expressed in mm Hg/ml/min, and may therefore result
from the particularly low TPR baseline after AdrX in this group.
The down-regulation of the TPR-response to tyramine observed
during the late part of the infusion-period was eliminated by
SR59230A in not-AdrX SHR (Figure 2).
DISCUSSION
The main result in the present study was that the β3AR agonist
BRL37344 reduced tyramine-stimulated norepinephrine over-
flow to plasma in SHR but not in WKY. BRL37344 also reduced
the positive inotropic response to tyramine. Most effects of the
antagonist SR59230A were likely to be due to inhibition of low-
affinity state β1AR (β1LAR), i.e., a reduced tyramine-stimulated
norepinephrine release in both strains, a reduced secretion of
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epinephrine in SHR and a reduced tyramine-induced tachy-
cardia in WKY. BRL37344 reduced TPR baseline in SHR, and
SR59230A prevented the down-regulation of the TPR-response
to tyramine, compatible with effects involving β3AR-eNOS- or
β1L/1/2AR-mediated vasodilatation. The results and deductions
are summarized in Table 2.
THE EFFECT OF β3AR-AGONIST AND -ANTAGONIST ON STIMULATED
NOREPINEPHRINE RELEASE
The influence of β3AR on catecholamine release was stud-
ied during tyramine-stimulated norepinephrine release since
βAR antagonist (propranolol) did not significantly alter the
low plasma catecholamine concentrations in unstimulated rats
FIGURE 2 | The TPR-response to tyramine in WKY and SHR,
without and after acute AdrX. The rats were pre-treated with the
β3AR antagonist SR59230A or agonist BRL37344 as indicated by
symbol legends. The TPR-results in the SR59230A-treated groups are
from Berg et al. (2010). ∗P ≤ 0.025 after curve evaluation (please
see Methods).
Table 2 | Effects of the agonist BRL37344 and the antagonist SR59230A, and possible interpretations of the results.
WKY AdrX WKY SHR AdrX SHR Possible mechanisms responsible for the results
BRL37344
Baselines: TF ∼ ∼ ↓ ↓ Pos. inotropy: ↑ β1/β2AR
TPR ∼ ↓ ∼ ↓ aVasorelaxation: ↑ β3AR-eNOS or ↑ VSMC β1/2AR-Gs
Tyramine: TF ∼ ∼ ↑ ∼ Neg. inotropy: ↑ β3AR-Gi or due to ↓NE release
TPR ∼ ∼ ∼ (↑) aVasoconstriction: Due to a low baseline?
Plasma NE ∼ ∼ ↓ ∼ Inhibition of release: ↑ β3AR-Gi
Plasma EPI ∼ ∼ ∼ ∼ No effect on adrenal epinephrine release
SR59230A
Baselines: TF ↓ ↓ ∼ ∼ Pos. inotropy, absent after CGP20712A+ICI-11855: ↑ β1AR-Gs
TPR ∼ ∼ ∼ ∼ No effect
Tyramine: TF ∼ ∼ ∼ ∼ No effect
HR ↓ ↓ ∼ ∼ Neg. chronotropy: ↓ β1LAR-Gs or due to ↓NE release
TPR ∼ ∼ ↑ ∼ ↓ βAR vasorelaxation: ↓ β3AR-eNOS and/or ↓ β1LAR-Gs
Plasma NE ↓ ∼ ↓ ∼ Inhibition of release: ↓ β1LAR-Gs
Plasma EPI ∼ ∼ ↓ ∼ Inhibition of release: ↓ β1LAR-Gs
aIn the absence of epinephrine-activated β2AR-mediated vasodilatation. NE, norepinephrine. EPI, epinephrine, secretion activated by the surgical trauma, not by
tyramine. ∼, unchanged parameter. Pos., positive. Neg., negative.
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(T. Berg, unpublished observations). As previously published
(Berg, 2014), the tyramine-stimulated norepinephrine overflow
was not different in AdrX rats of either strain, showing that
the released norepinephrine originated from peripheral sympa-
thetic nerves rather than the adrenals. The agonist BRL37344 had
no effect on the tyramine-stimulated norepinephrine overflow
in WKY, but reduced overflow in SHR. This was not explained
by the weak β1- and β2AR agonistic effect of BRL37344 (Dolan
et al., 1994), since such activity would be expected to enhance
release. BRL37344 may therefore inhibit norepinephrine release
by stimulating β3AR-coupling to Gi, similar to that described
for the β3AR-mediated inhibition of cardiomyocyte contraction
(Gauthier et al., 1996). These inhibitory β3AR were likely to
be located presynaptically on peripheral sympathetic nerve end-
ings, similar to that described for the facilitating β1AR and β2AR
(Westfall, 1977; Starke et al., 1989; Berg, 2014).
Similar to that previously described for both β1- and β2AR
antagonists (Berg et al., 2010; Berg, 2014), also the β3AR antag-
onist SR59230A reduced the tyramine-induced norepinephrine
overflow in WKY and SHR. Any β1AR agonistic effect of
SR59230A (Malinowska and Schlicker, 1997) would be expected
to increase norepinephrine overflow. Thus, opposite of what was
expected from the effect of BRL37344, and under the same con-
ditions, SR59230A inhibited a release-stimulating mechanism. In
addition, unlike the β3AR-Gi-signaling suggested by BRL37344,
this stimulating mechanism was present in both strains. However,
SR59230A has been shown in vivo to inhibit an atypical, puta-
tive, Gs-coupled, cardio-stimulating βAR with equal efficacy as it
inhibited β3AR-mediated thermogenesis, whereas the same recep-
tor was only marginally stimulated by BRL37344 (Malinowska
and Schlicker, 1997). This putative βAR has now been recognized
to represent β1LAR (Granneman, 2001; Kaumann et al., 2001).
Since norepinephrine release has been shown to be reduced by
β1AR antagonists such as atenolol and metoprolol and also the
β1LAR antagonist CGP20712A (Berg, 2014; Berg et al., 2010), it
seemed reasonable to conclude that the reduced norepinephrine
overflow in SR59230A-treated rats resulted from inhibition of
presynaptic β1LAR.
SR59230A and BRL37344 did not significantly influence the
tyramine-stimulated norepinephrine overflow to plasma in AdrX
rats of either strain. This observation may indicate that circu-
lating epinephrine was in fact the agonist responsible for the
β1LAR-activity, at least in WKY, and that the effect of β3AR ago-
nist/antagonist on norepinephrine release was indirect and due
to an effect on the secretion of epinephrine. However, as dis-
cussed below, a significant change in the plasma epinephrine
concentration was observed only in the SR59230A-pre-treated
SHR. β1+ 2AR inhibition, i.e., CGP20712A and ICI-118551 com-
bined, reduced overflow in AdrX WKY, although the difference
was not statistically significant, and additional pre-treatment
with SR59230A resulted in a similar, significant reduction in
the plasma norepinephrine concentration. An additive effect of
βAR antagonist directed against more than one subtype may
not have been expected since the reduction following inhibition
of β1AR and β2AR separately was not different from that after
inhibition of both (Berg, 2014). However, pre-treatment with
CGP20712A+ICI-118551, alone or combined with SR59230A,
did not reduce norepinephrine overflow in AdrX SHR. Thus,
AdrX altered the ability of not only the β3AR, but also that of
β1+ 2AR, to stimulate norepinephrine release. This changemay be
due to that AdrX altered the balance between the βAR and other
mechanism(s) influencing norepinephrine release, for instance
α2AR-mediated inhibition of release. This possibility is presently
under investigation.
THE EFFECT OF β3AR-AGONIST AND -ANTAGONIST ON EPINEPHRINE
RELEASE
The plasma concentration at the end of the experiment in time
controls was higher than that in plasma from anesthetized rats
not subjected to surgery other than femoral artery catheteriza-
tion (0.1 ± 0.1 nM in both WKY and SHR compared to 6–10 nM
in the time controls, P < 0.001) (Berg et al., 2012). It was there-
fore concluded that the adrenal secretion of epinephrine in this
experimental model was activated by the surgical trauma. Also
this release was sensitive to α2AR auto-inhibition (Berg, 2013;
Berg and Jensen, 2013). Pre-treatment with SR59230A, but not
BRL37344, reduced the plasma concentration of epinephrine,
with a statistically significant difference detected only in SHR.
The secretion of epinephrine in SHR therefore appeared to be
enhanced by the β1LAR. SR59230A, like the β2AR antagonist ICI-
118551, also reduced basal and stimulated catecholamine release
in human adrenal, isolated chromaffin cells, indicating a β2- and
β3AR-mediated stimulation of release (Cortez et al., 2012). Unless
the β3AR influence on epinephrine and norepinephrine release in
the rat differed by coupling to Gs and Gi, respectively, it may be
considered that SR59230A may inhibit the β1LAR also in human
chromaffin cells.
THE EFFECT OF β3AR-AGONIST AND -ANTAGONIST ON
CARDIOVASCULAR BASELINES
BRL37344 induced a decrease in baseline TF in SHR but not
WKY, indicating a positive inotropic effect. The same response
was observed also in AdrX SHR. Without stimulation of nore-
pinephrine release, overflow to plasma in anesthetized rats was
very low, even in the presence of desipramine, an inhibitor
of synaptic norepinephrine re-uptake (Berg et al., 2012). If
β3AR-activation depended on a high catecholamine concentra-
tion and, from that, a catecholamine-induced receptor rear-
rangement, the β3AR may not be present in sufficient quan-
tity in the basal condition to mediate a negative inotropic
response. The positive inotropy may therefore without stimu-
lation of norepinephrine release result from the weak β1+ 2AR
agonistic effect of BRL37344 (Dolan et al., 1994). BRL37344 in
addition induced a fall in TPR baseline in AdrX rats of both
strains. Thus, in the absence of the β2AR-mediated vasodilatory
component, BRL37344 induced vasodilatation, either through
a VSMC β1/2AR-Gs-cAMP-dependent mechanism or, perhaps
more likely, through endothelial β3AR-eNOS activation (Mallem
et al., 2005).
SR59230A reduced baseline TF in both not-AdrX and
AdrX WKY, but not in SHR, demonstrating an increase in
inotropy, suggesting the presence of a β3AR-Gi-mediated, nega-
tive inotropic component in the unstimulated WKY (Berg et al.,
2010). However, SR59230A has been shown to have some β1AR
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agonistic effect (Malinowska and Schlicker, 1997), which will be
expected to enhance inotropy and thus lower TF. This explanation
was supported by the fact that SR59230A did not lower base-
line TF after prior administration of β1+ 2AR antagonists in AdrX
WKY. Thus, what appeared to indicate a SR59230A-induced inhi-
bition of a β3AR-Gi-mediated negative inotropy, as we previously
concluded (Berg et al., 2010), may just as well be due to β1AR
activation.
THE EFFECT OF β3AR-AGONIST AND -ANTAGONIST ON THE
CARDIOVASCULAR RESPONSE TO STIMULATED NOREPINEPHRINE
RELEASE
When the release of large amounts of norepinephrine was stim-
ulated by tyramine, the results differed from that observed in the
basal condition. BRL37344 increased TF in tyramine-stimulated
SHR but not in AdrX SHR or WKY, indicating that BRL37344
in SHR hampered the positive inotropic effect of tyramine. Thus,
selective β3AR stimulation with agonist in the presence of high
concentrations of norepinephrine and circulating epinephrine
appeared to evoke coupling to Gi, possibly functioning as a
“safety valve” against excessive stimulation. This may be due to
a direct effect on the cardiomyocytes, but may also be explained
by the parallel reduction in norepinephrine release, which also
was observed only in the not-AdrX SHR group. A reduction in
norepinephrine release may also explain the previously docu-
mented inhibitory effect of SR59220A on the tyramine-induced
tachycardia inWKY (Berg et al., 2010). The SR59230A-dependant
inhibition of the down-regulation of the late TPR-response to
tyramine in not-AdrX SHR was compatible with an up-regulated
β3AR expression in SHR, and a SR59230A-dependant inhibition
of β3AR-eNOS induced vasodilatation. However, it cannot be
excluded that the latter two effects of SR59230Amay be explained
by inhibition of βILAR-Gs-signaling, since also the β1AR antago-
nist CGP20712A reduced the tyramine-induced tachycardia and
prevented the down-regulation of the late TPR-response (Berg
et al., 2010).
CONCLUSIONS
From the present results it may be deduced that effects explained
by a β3AR-Gi-signaling, i.e., inhibition of norepinephrine release
and negative inotropy, was only observed after stimulation with
the agonist BRL37344, and then only in SHR during tyramine-
stimulated release of norepinephrine. In the absence of selective,
exogenous β3AR agonist, the response to tyramine-stimulated
norepinephrine release predominantly involved βILAR, such as
stimulation of norepinephrine release in both strains, secretion of
epinephrine from the adrenal glands in SHR and norepinephrine-
induced tachycardia in WKY. These responses were inhibited
by SR59230A, which antagonizes β1LAR equally well as β3AR.
In situations such as heart failure, acute myocardial infarction
and arrhythmia, where the release of norepinephrine is greatly
increased, BRL37344 and SR59230A may both provide relief by
reducing norepinephrine release.
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